Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
10.85
+0.11 (1.02%)
Jul 30, 2026, 3:00 PM CST
SHA:603079 Revenue
Zhejiang Shengda Bio-Pharm had revenue of 189.22M CNY in the quarter ending March 31, 2026, a decrease of -13.41%. This brings the company's revenue in the last twelve months to 830.53M, down -1.81% year-over-year. In the year 2025, Zhejiang Shengda Bio-Pharm had annual revenue of 844.54M with 2.07% growth.
Revenue (ttm)
830.53M
Revenue Growth
-1.81%
P/S Ratio
2.45
Revenue / Employee
766.88K
Employees
1,083
Market Cap
2.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 844.54M | 17.13M | 2.07% |
| Dec 31, 2024 | 827.40M | 100.00M | 13.75% |
| Dec 31, 2023 | 727.41M | -10.61M | -1.44% |
| Dec 31, 2022 | 738.02M | -51.71M | -6.55% |
| Dec 31, 2021 | 789.73M | -77.58M | -8.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enwei Pharmaceutical | 879.60M |
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 862.85M |
| Hainan Huluwa Pharmaceutical Group | 710.14M |
| Zhejiang Shapuaisi Pharmaceutical | 459.57M |
| Anhui Huangshan Capsule | 437.17M |
| Guhan Pharmaceutical Group | 344.12M |
| Qinghai Spring Medicinal Resources Technology | 303.67M |
| Shandong Sinobioway Biomedicine | 283.34M |